These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17494054)

  • 1. BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma.
    Hu LL; Wang XX; Chen X; Chang J; Li C; Zhang Y; Yang J; Jiang W; Zhuang SM
    Carcinogenesis; 2007 Aug; 28(8):1740-4. PubMed ID: 17494054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma.
    Korenaga Y; Naito K; Okayama N; Hirata H; Suehiro Y; Hamanaka Y; Matsuyama H; Hinoda Y
    Int J Cancer; 2005 Nov; 117(3):431-4. PubMed ID: 15906349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases.
    Fischer S; Lakatos PL; ; Lakatos L; Kovacs A; Molnar T; Altorjay I; Papp M; Szilvasi A; Tulassay Z; Osztovits J; Papp J; Demeter P; Schwab R; Tordai A; Andrikovics H
    Scand J Gastroenterol; 2007 Jun; 42(6):726-33. PubMed ID: 17505995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis.
    Cao HY; Zou P; Zhou H
    Gene; 2013 May; 519(2):288-94. PubMed ID: 23485354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
    Imai Y; Nakane M; Kage K; Tsukahara S; Ishikawa E; Tsuruo T; Miki Y; Sugimoto Y
    Mol Cancer Ther; 2002 Jun; 1(8):611-6. PubMed ID: 12479221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between the ABCG2 C421A polymorphism and Alzheimer's disease.
    Fehér Á; Juhász A; László A; Pákáski M; Kálmán J; Janka Z
    Neurosci Lett; 2013 Aug; 550():51-4. PubMed ID: 23827224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H2AFX polymorphisms are associated with decreased risk of diffuse large B cell lymphoma in Koreans.
    Jin XM; Kim HN; Shin MH; Lee IK; Lee JS; Lee JH; Kim HJ; Choi JS; Juhng SW; Choi C
    DNA Cell Biol; 2011 Dec; 30(12):1039-44. PubMed ID: 21631283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD38 and interleukin 6 gene polymorphism in egyptians with diffuse large B-cell lymphoma (DLBCL).
    Talaat RM; Abdel-Aziz AM; El-Maadawy EA; Abdel-Bary N
    Immunol Invest; 2015; 44(3):265-78. PubMed ID: 25564959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.
    Yanase K; Tsukahara S; Mitsuhashi J; Sugimoto Y
    Cancer Lett; 2006 Mar; 234(1):73-80. PubMed ID: 16303243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of MNS16A VNTR and hTERT rs2736098: G>A polymorphisms with susceptibility to diffuse large B-cell lymphoma.
    Essa ES; Alagizy HA
    Tumori; 2018 Jun; 104(3):165-171. PubMed ID: 28967095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population.
    Østergaard M; Ernst A; Labouriau R; Dagiliené E; Krarup HB; Christensen M; Thorsgaard N; Jacobsen BA; Tage-Jensen U; Overvad K; Autrup H; Andersen V
    Scand J Gastroenterol; 2009; 44(1):65-73. PubMed ID: 18819034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
    Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.
    Adkison KK; Vaidya SS; Lee DY; Koo SH; Li L; Mehta AA; Gross AS; Polli JW; Humphreys JE; Lou Y; Lee EJ
    J Pharm Sci; 2010 Feb; 99(2):1046-62. PubMed ID: 19569219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDR1 polymorphisms associated with risk and survival in diffuse large B-cell lymphoma.
    Hu LL; Yu B; Yang J
    Leuk Lymphoma; 2013 Jun; 54(6):1188-93. PubMed ID: 23088763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human leukocyte antigen-G polymorphisms influence the clinical outcome in diffuse large B-cell lymphoma.
    Bielska M; Bojo M; Klimkiewicz-Wojciechowska G; Jesionek-Kupnicka D; Borowiec M; Kalinka-Warzocha E; Prochorec-Sobieszek M; Robak T; Warzocha K; Młynarski W; Lech-Maranda E
    Genes Chromosomes Cancer; 2015 Mar; 54(3):185-93. PubMed ID: 25620080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy.
    Wu H; Liu Y; Kang H; Xiao Q; Yao W; Zhao H; Wang E; Wei M
    Biomed Res Int; 2015; 2015():279109. PubMed ID: 26634205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional interleukin-21 polymorphism is a protective factor of diffuse large B-cell lymphoma.
    Wang H; Wang M; Feng Z; Chen L; Gao L; Li Q; Zhang L; Ma J
    DNA Cell Biol; 2014 Nov; 33(11):775-80. PubMed ID: 25126827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms.
    Poonkuzhali B; Lamba J; Strom S; Sparreboom A; Thummel K; Watkins P; Schuetz E
    Drug Metab Dispos; 2008 Apr; 36(4):780-95. PubMed ID: 18180275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma.
    Lech-Maranda E; Baseggio L; Bienvenu J; Charlot C; Berger F; Rigal D; Warzocha K; Coiffier B; Salles G
    Blood; 2004 May; 103(9):3529-34. PubMed ID: 14701701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East.
    Siraj AK; Ibrahim M; Al-Rasheed M; Bu R; Bavi P; Jehan Z; Abubaker J; Murad W; Al-Dayel F; Ezzat A; El-Solh H; Uddin S; Al-Kuraya K
    Ann Hematol; 2007 Dec; 86(12):887-95. PubMed ID: 17712558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.